{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:42:34Z","timestamp":1792557754287,"version":"4.5.0"},"reference-count":135,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["#02103266"],"award-info":[{"award-number":["#02103266"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004410","name":"European Molecular Biology Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first-line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.<\/jats:p>","DOI":"10.1093\/neuonc\/noag227","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:13:35Z","timestamp":1789672415000},"source":"Crossref","is-referenced-by-count":0,"title":["Immune cell engager therapy for brain cancer"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1702-9049","authenticated-orcid":false,"given":"Daan A","family":"Sluijter","sequence":"first","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"van Garderen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"van Haveren","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Meeldijk","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Center for Translational Immunology, University\u00a0Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-1408","authenticated-orcid":false,"given":"Sandra","family":"Crnko","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-3353","authenticated-orcid":false,"given":"Thijs","family":"Koorman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toine","family":"ten Broeke","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-4355","authenticated-orcid":false,"given":"Michael Y","family":"Schakelaar","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8526-4456","authenticated-orcid":false,"given":"Niels","family":"Bovenschen","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht,","place":["The Netherlands"]},{"name":"Center for Translational Immunology, University\u00a0Medical Center Utrecht , Utrecht,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026102100324380900_noag227-B1","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.ncl.2016.06.014","article-title":"Epidemiology of brain tumors","volume":"34","author":"McNeill","year":"2016","journal-title":"Neurol Clin"},{"key":"2026102100324380900_noag227-B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026102100324380900_noag227-B4","first-page":"1","article-title":"Declines in cancer death rates among children and adolescents in the United States, 1999-2014","author":"Curtin","year":"2016","journal-title":"NCHS Data Brief"},{"key":"2026102100324380900_noag227-B5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11910-023-01316-9","article-title":"Recent advances in pediatric medulloblastoma","volume":"23","author":"Jackson","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026102100324380900_noag227-B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3171\/2019.5.peds18381","article-title":"Medulloblastoma in the age of molecular subgroups: a review","volume":"24","author":"Juraschka","year":"2019","journal-title":"J Neurosurg Pediatr"},{"key":"2026102100324380900_noag227-B7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41568-022-00486-x","article-title":"Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity","volume":"22","author":"Gimple","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2026102100324380900_noag227-B8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol"},{"key":"2026102100324380900_noag227-B9","doi-asserted-by":"publisher","first-page":"1012841","DOI":"10.3389\/fimmu.2023.1012841","article-title":"Nanobodies in cell-mediated immunotherapy: on the road to fight cancer","volume":"14","author":"Maali","year":"2023","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10030360","article-title":"Bispecific antibodies and antibody\u2013drug conjugates for cancer therapy: technological considerations","volume":"10","author":"Shim","year":"2020","journal-title":"Biomolecules"},{"key":"2026102100324380900_noag227-B12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol Med"},{"key":"2026102100324380900_noag227-B13","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2026102100324380900_noag227-B14","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"2026102100324380900_noag227-B15","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J Biol Chem"},{"key":"2026102100324380900_noag227-B16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B17","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3389\/fimmu.2017.01442","article-title":"Nanobody-based delivery systems for diagnosis and targeted tumor therapy","volume":"8","author":"Hu","year":"2017","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B18","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"2026102100324380900_noag227-B19","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1182\/blood-2018-99-118136","article-title":"A phase 1 study investigating AFM11 in patients with relapsed\/refractory B cell precursor acute lymphoblastic leukemia: preliminary results","volume":"132","author":"Salogub","year":"2018","journal-title":"Blood"},{"key":"2026102100324380900_noag227-B20","doi-asserted-by":"publisher","first-page":"ltae005","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunother Adv"},{"key":"2026102100324380900_noag227-B21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3390\/cancers16081580","article-title":"Cell engagers\u2014the structure and functional principle and application in hematological malignancies","volume":"16","author":"Cech","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026102100324380900_noag227-B22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell\u2013cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026102100324380900_noag227-B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003679","article-title":"For whom the T cells troll? Bispecific T-cell engagers in glioblastoma","volume":"9","author":"Singh","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2016.391","article-title":"Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors","volume":"31","author":"Aldoss","year":"2017","journal-title":"Leukemia"},{"key":"2026102100324380900_noag227-B25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"2026102100324380900_noag227-B26","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"2026102100324380900_noag227-B27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/19420862.2016.1210747","article-title":"Fab-dsFv: a bispecific antibody format with extended serum half-life through albumin binding","volume":"8","author":"Dav\u00e9","year":"2016","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B28","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.1096\/fj.201903231R","article-title":"Serum albumin-binding VHHs with variable pH sensitivities enable tailored half-life extension of biologics","volume":"34","author":"van Faassen","year":"2020","journal-title":"Faseb J"},{"key":"2026102100324380900_noag227-B29","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026102100324380900_noag227-B30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B31","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol Oncol"},{"key":"2026102100324380900_noag227-B33","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1038\/onc.2011.563","article-title":"EGFRvIII promotes glioma angiogenesis and growth through the NF-B, interleukin-8 pathway","volume":"31","author":"Bonavia","year":"2012","journal-title":"Oncogene"},{"key":"2026102100324380900_noag227-B34","first-page":"5079","article-title":"A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis","volume":"56","author":"Nagane","year":"1996","journal-title":"Cancer Res"},{"key":"2026102100324380900_noag227-B35","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"2026102100324380900_noag227-B36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1073\/pnas.1219817110","article-title":"Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma","volume":"110","author":"Choi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102100324380900_noag227-B37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1535-7163.MCT-20-0508","article-title":"Preclinical assessment of AMG 596, a bispecific T-cell engager (BiTE) immunotherapy targeting the tumor-specific antigen EGFRvIII","volume":"20","author":"Sternjak","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026102100324380900_noag227-B38","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1158\/1078-0432.CCR-17-0126","article-title":"A rationally designed fully human EGFRvIII: CD3-targeted bispecific antibody redirects human T cells to treat patient-derived intracerebral malignant glioma","volume":"24","author":"Gedeon","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026102100324380900_noag227-B39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fonc.2017.00100","article-title":"Highly specific and effective targeting of EGFRvIII-positive tumors with TandAb antibodies","volume":"7","author":"Ellwanger","year":"2017","journal-title":"Front Oncol"},{"key":"2026102100324380900_noag227-B40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001202","article-title":"Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma","volume":"8","author":"Gardell","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omto.2023.02.004","article-title":"Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape","volume":"28","author":"Park","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"2026102100324380900_noag227-B42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026102100324380900_noag227-B43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-024-04564-y","article-title":"Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide","volume":"166","author":"Fadul","year":"2024","journal-title":"J Neurooncol"},{"key":"2026102100324380900_noag227-B45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro Oncol"},{"key":"2026102100324380900_noag227-B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22134","article-title":"Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy","volume":"1","author":"Kioi","year":"2006","journal-title":"Cancer."},{"key":"2026102100324380900_noag227-B47","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13R\u03b12 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One"},{"key":"2026102100324380900_noag227-B48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11060-017-2680-9","article-title":"Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor \u03b11 and \u03b12 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme","volume":"136","author":"Han","year":"2018","journal-title":"J Neurooncol"},{"key":"2026102100324380900_noag227-B49","doi-asserted-by":"publisher","first-page":"24915","DOI":"10.1074\/jbc.M502571200","article-title":"Characterization of the interaction between interleukin-13 and interleukin-13 receptors","volume":"280","author":"Arima","year":"2005","journal-title":"J Biol Chem"},{"key":"2026102100324380900_noag227-B50","doi-asserted-by":"publisher","author":"Zannikou","DOI":"10.1136\/jitc-2025-011714"},{"key":"2026102100324380900_noag227-B51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.omto.2022.07.003","article-title":"In vivo DNA-launched bispecific T cell engager targeting IL-13R\u03b12 controls tumor growth in an animal model of glioblastoma multiforme","volume":"26","author":"Bhojnagarwala","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"2026102100324380900_noag227-B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2015800118","article-title":"Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity","volume":"118","author":"Pituch","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102100324380900_noag227-B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2026.201201","article-title":"Enabling CAR-T cell immunotherapy in glioblastoma by modifying tumor microenvironment via oncolytic adenovirus encoding bispecific T cell engager","author":"Choi","journal-title":"Mol Ther Oncol"},{"key":"2026102100324380900_noag227-B54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009604","article-title":"Novel tri-specific T-cell engager targeting IL-13R\u03b12 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells","volume":"12","author":"Park","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009901","article-title":"Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response","volume":"12","author":"Zhu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B56","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026102100324380900_noag227-B57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","article-title":"Pediatric medulloblastoma express immune checkpoint B7-H3","volume":"24","author":"Li","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"2026102100324380900_noag227-B58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026102100324380900_noag227-B59","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026102100324380900_noag227-B60","doi-asserted-by":"publisher","first-page":"e1326437","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026102100324380900_noag227-B61","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.3390\/cancers12123827","article-title":"Convergent evolution by cancer and viruses in evading the nkg2d immune response","volume":"12","author":"Baugh","year":"2020","journal-title":"Cancers (Basel))"},{"key":"2026102100324380900_noag227-B62","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-032712-095951","article-title":"Regulation of ligands for the NKG2D activating receptor","volume":"31","author":"Raulet","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2026102100324380900_noag227-B63","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fonc.2013.00094","article-title":"In vitro natural killer cell immunotherapy for medulloblastoma","volume":"3","author":"Fern\u00e1ndez","year":"2013","journal-title":"Front Oncol"},{"key":"2026102100324380900_noag227-B64","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008460","article-title":"Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells","volume":"12","author":"Baugh","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B65","doi-asserted-by":"publisher","first-page":"1983306","DOI":"10.1080\/2162402X.2021.1983306","article-title":"Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma","volume":"10","author":"Li","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026102100324380900_noag227-B66","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s11427-024-2591-7","article-title":"CD87-targeted BiTE and CAR-T cells potently inhibit invasive nonfunctional pituitary adenomas","volume":"67","author":"Ren","year":"2024","journal-title":"Sci China Life Sci"},{"key":"2026102100324380900_noag227-B67","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.2174\/138161210793429788","article-title":"Modulation of carbonic anhydrase 9 (CA9) in human brain cancer","volume":"16","author":"M, Said","year":"2010","journal-title":"Curr Pharm Des"},{"key":"2026102100324380900_noag227-B68","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/nos216","article-title":"Function of carbonic anhydrase IX in glioblastoma multiforme","volume":"14","author":"Proescholdt","year":"2012","journal-title":"Neuro Oncol"},{"key":"2026102100324380900_noag227-B69","doi-asserted-by":"publisher","first-page":"905768","DOI":"10.3389\/fimmu.2022.905768","article-title":"Dual antigen T cell engagers targeting CA9 as an effective immunotherapeutic modality for targeting CA9 in solid tumors","volume":"13","author":"Tatari","year":"2022","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B70","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"2026102100324380900_noag227-B71","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"2026102100324380900_noag227-B72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-5-67","article-title":"Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma","volume":"5","author":"Liu","year":"2006","journal-title":"Mol Cancer"},{"key":"2026102100324380900_noag227-B73","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","article-title":"The rational development of CD133-targeting immunotherapies for glioblastoma","volume":"26","author":"Vora","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2026102100324380900_noag227-B74","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/0008-5472.CAN-14-2415","article-title":"Effective eradication of glioblastoma stem cells by local application of an AC133\/CD133-specific T-cell-engaging antibody and CD8 T cells","volume":"75","author":"Prasad","year":"2015","journal-title":"Cancer Res"},{"key":"2026102100324380900_noag227-B75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11523-015-0391-8","article-title":"Heterodimeric bispecific single chain variable fragments (scFv) killer engagers (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells","volume":"11","author":"Schmohl","year":"2016","journal-title":"Target Oncol"},{"key":"2026102100324380900_noag227-B76","doi-asserted-by":"publisher","first-page":"e00020","DOI":"10.1097\/IN9.0000000000000020","article-title":"Metabolic regulation of NK cell function: implications for immunotherapy","volume":"5","author":"Sohn","year":"2023","journal-title":"Immunometabolism (United States)"},{"key":"2026102100324380900_noag227-B77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","article-title":"Interleukin-15 biology and its therapeutic implications in cancer","volume":"33","author":"Steel","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2026102100324380900_noag227-B78","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B79","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol Cancer"},{"key":"2026102100324380900_noag227-B80","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"2026102100324380900_noag227-B81","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ymthe.2025.02.043","article-title":"Killing the killers: natural killer cell therapy targeting glioma stem cells in high-grade glioma","volume":"33","author":"Poorva","year":"2025","journal-title":"Mol Ther"},{"key":"2026102100324380900_noag227-B82","doi-asserted-by":"publisher","first-page":"e31959","DOI":"10.1371\/journal.pone.0031959","article-title":"Cytotoxicity of CD56 bright NK cells towards autologous activated CD4 + T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94\/NKG2A","volume":"7","author":"Nielsen","year":"2012","journal-title":"PLoS One"},{"key":"2026102100324380900_noag227-B83","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/cyto.a.22589","article-title":"Cellular immune surveillance of central nervous system bypasses blood-brain barrier and blood-cerebrospinal-fluid barrier: revealed with the New Marburg cerebrospinal-fluid model in healthy humans","volume":"87","author":"Kleine","year":"2015","journal-title":"Cytometry A"},{"key":"2026102100324380900_noag227-B84","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s42003-022-03402-z","article-title":"Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem-like tumorospheres","volume":"5","author":"Breznik","year":"2022","journal-title":"Commun Biol"},{"key":"2026102100324380900_noag227-B85","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-016-0272-3","article-title":"Immune phenotypes predict survival in patients with glioblastoma multiforme","volume":"9","author":"Mostafa","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2026102100324380900_noag227-B86","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fonc.2018.00513","article-title":"Carbohydrate targets for CAR T cells in solid childhood cancers","volume":"8","author":"Rossig","year":"2018","journal-title":"Front Oncol"},{"key":"2026102100324380900_noag227-B87","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/nejmoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2026102100324380900_noag227-B89","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1038\/s41467-024-51337-2","article-title":"CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma","volume":"15","author":"Pascual-Pasto","year":"2024","journal-title":"Nat Commun"},{"key":"2026102100324380900_noag227-B90","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131716","article-title":"Bi-specific killer cell engager enhances NK cell activity against interleukin-13 receptor alpha-2 positive gliomas","volume":"12","author":"Pawlowski","year":"2023","journal-title":"Cells"},{"key":"2026102100324380900_noag227-B91","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin Transl Med"},{"key":"2026102100324380900_noag227-B92","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11899-021-00628-2","article-title":"Chimeric antigen receptor\u2013modified T cells and T cell\u2013engaging bispecific antibodies: different tools for the same job","volume":"16","author":"Schwerdtfeger","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"2026102100324380900_noag227-B93","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/vaccines10081335","article-title":"Development of a bispecific nanobody targeting CD20 on B-cell lymphoma cells and CD3 on T cells","volume":"10","author":"Liu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026102100324380900_noag227-B94","doi-asserted-by":"publisher","first-page":"838406","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B95","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026102100324380900_noag227-B96","doi-asserted-by":"publisher","first-page":"108132","DOI":"10.1016\/j.isci.2023.108132","article-title":"Exit pathways of therapeutic antibodies from the brain and retention strategies","volume":"26","author":"Schellhammer","year":"2023","journal-title":"iScience"},{"key":"2026102100324380900_noag227-B97","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood\u2013brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"2026102100324380900_noag227-B98","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","article-title":"Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target","volume":"3","author":"Yu","year":"2011","journal-title":"Sci Transl Med"},{"key":"2026102100324380900_noag227-B99","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.nucmedbio.2022.04.002","article-title":"Passive and receptor mediated brain delivery of an anti-GFAP nanobody","volume":"114-115","author":"Meier","year":"2022","journal-title":"Nucl Med Biol"},{"key":"2026102100324380900_noag227-B100","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11060-024-04795-z","article-title":"Focused ultrasound-mediated enhancement of blood\u2013brain barrier permeability for brain tumor treatment: a systematic review of clinical trials","volume":"170","author":"Zhu","year":"2024","journal-title":"J Neurooncol"},{"key":"2026102100324380900_noag227-B101","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/ph17080973","article-title":"A review of therapeutic agents given by convection-enhanced delivery for adult glioblastoma","volume":"17","author":"Rolfe","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026102100324380900_noag227-B102","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026102100324380900_noag227-B103","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","article-title":"Natural killer cells unleashed: checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy","volume":"31","author":"Davis","year":"2017","journal-title":"Semin Immunol"},{"key":"2026102100324380900_noag227-B104","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/1078-0432.CCR-13-0505","article-title":"Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16\u2009\u00d7\u200933 bispecific killer cell engager and ADAM17 inhibition","volume":"19","author":"Wiernik","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026102100324380900_noag227-B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02884-6","article-title":"Antibody-lectin chimeras for glyco-immune checkpoint blockade","author":"Stark","year":"2025","journal-title":"Nat Biotechnol"},{"key":"2026102100324380900_noag227-B106","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s43018-023-00598-9","article-title":"Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response","volume":"4","author":"Mei","year":"2023","journal-title":"Nat Cancer"},{"key":"2026102100324380900_noag227-B107","doi-asserted-by":"publisher","first-page":"eadf5302","DOI":"10.1126\/scitranslmed.adf5302","article-title":"Targeting the siglec-sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma","volume":"15","author":"Schmassmann","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026102100324380900_noag227-B108","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s43018-025-01070-6","article-title":"Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy","volume":"6","author":"Giovannoni","year":"2025","journal-title":"Nat Cancer"},{"key":"2026102100324380900_noag227-B109","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"2026102100324380900_noag227-B110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40478-022-01326-7","article-title":"Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs","volume":"10","author":"Lee","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"2026102100324380900_noag227-B111","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/cas.13990","article-title":"Hypoxia\/pseudohypoxia-mediated activation of hypoxia-inducible factor-1\u03b1 in cancer","volume":"110","author":"Hayashi","year":"2019","journal-title":"Cancer Sci"},{"key":"2026102100324380900_noag227-B112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.trecan.2022.09.005","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Trends Cancer"},{"key":"2026102100324380900_noag227-B113","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3324\/haematol.2023.283758","article-title":"Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Haematologica"},{"key":"2026102100324380900_noag227-B114","doi-asserted-by":"publisher","first-page":"2381261","DOI":"10.1080\/19420862.2024.2381261","article-title":"Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers","volume":"16","author":"Liao","year":"2024","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B115","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1182\/blood-2018-99-118427","article-title":"CD16A-Specific tetravalent bispecific immune cell engagers potently induce antibody-dependent cellular phagocytosis (ADCP) on macrophages","volume":"132","author":"Wingert","year":"2018","journal-title":"Blood"},{"key":"2026102100324380900_noag227-B116","doi-asserted-by":"publisher","first-page":"1039969","DOI":"10.3389\/fimmu.2022.1039969","article-title":"Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy","volume":"13","author":"Nikkhoi","year":"2023","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B117","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res"},{"key":"2026102100324380900_noag227-B118","doi-asserted-by":"publisher","first-page":"588552","DOI":"10.3389\/fimmu.2020.588552","article-title":"PD-L1-mediated immunosuppression in glioblastoma is associated with the infiltration and M2-polarization of tumor-associated macrophages","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"2026102100324380900_noag227-B119","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026102100324380900_noag227-B120","doi-asserted-by":"publisher","first-page":"2584374","DOI":"10.1080\/19420862.2025.2584374","article-title":"Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2\u2009+\u20091 TCBs","volume":"17","author":"Abdelmotaleb","year":"2025","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B121","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026102100324380900_noag227-B122","doi-asserted-by":"publisher","first-page":"2394229","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"MAbs"},{"key":"2026102100324380900_noag227-B123","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026102100324380900_noag227-B124","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jtho.2025.02.023","article-title":"Rapid intracranial response with tarlatamab in patients with untreated brain metastases from SCLC\u2014A real-world case series: case report","volume":"20","author":"Zhang","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026102100324380900_noag227-B125","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/neuonc\/noae160","article-title":"The emerging field of viroimmunotherapy for pediatric brain tumors","volume":"26","author":"Garcia-Moure","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026102100324380900_noag227-B126","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/nejmoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"2026102100324380900_noag227-B127","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026102100324380900_noag227-B128","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat Commun"},{"key":"2026102100324380900_noag227-B129","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"2026102100324380900_noag227-B130","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-021-01075-5","article-title":"Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies","volume":"14","author":"Heidbuechel","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026102100324380900_noag227-B131","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: first approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"2026102100324380900_noag227-B132","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nbt937","article-title":"Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins","volume":"22","author":"Yu","year":"2004","journal-title":"Nat Biotechnol"},{"key":"2026102100324380900_noag227-B133","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"2026102100324380900_noag227-B134","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01719-17","article-title":"Isolation and characterization of v\u0394I3 confirm that vaccinia virus SSB plays an essential role in viral replication","volume":"92","author":"Greseth","year":"2018","journal-title":"J Virol"},{"key":"2026102100324380900_noag227-B135","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s12094-021-02762-y","article-title":"Pediatric medulloblastoma express immune checkpoint B7-H3","volume":"24","author":"Li","year":"2022","journal-title":"Clin Transl Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag227\/71225695\/noag227.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag227\/71225695\/noag227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:32:58Z","timestamp":1792557178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag227\/8817228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":135,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag227","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"noag227"}}